Analysis of Atypical Antipsychotics-Induced Adverse Events Related to Diabetes Mellitus in Patients With Dementia Using the Japanese Adverse Drug Event Report Database
CONCLUSION AND RELEVANCE: The AAPs may cause DMAEs in patients with dementia. Low doses of quetiapine may induce DMAEs. Health care workers should focus on the development of DMAEs during the early administration period of AAPs. These results may assist with the safe management of patients with dementia who use AAPs.PMID:38124305 | DOI:10.1177/10600280231213507 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - December 21, 2023 Category: Drugs & Pharmacology Authors: Fuga Habuchi Natsuko Ishida Ryo Matsushita Junko Ishizaki Yukio Suga Source Type: research
Latency Antibiotics in Preterm Prelabor Rupture of Membranes: A Comparison of Azithromycin Regimens
CONCLUSIONS AND RELEVANCE: There was no difference in latency for patients who received a 5-day course of azithromycin versus a single dose for the treatment of PPROM. A higher rate of histologic chorioamnionitis was observed in those who received the single-day course. Prospective follow-up studies are needed to confirm these findings.PMID:38124306 | DOI:10.1177/10600280231181135 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - December 21, 2023 Category: Drugs & Pharmacology Authors: Kimberly N Day Julie A Vircks Christine E Henricks Kaci M Reaves Ashley K Holmes Karen L Florio Source Type: research
Lecanemab: A Humanized Monoclonal Antibody for the Treatment of Early Alzheimer Disease
CONCLUSION: Lecanemab is a humanized monoclonal antibody that is selective for soluble amyloid-beta (Aβ) aggregates. Lecanemab has exhibited a decrease in brain Aβ plaques and moderately less decline on clinical measures of cognitive function.PMID:38095619 | DOI:10.1177/10600280231218253 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - December 14, 2023 Category: Drugs & Pharmacology Authors: Juliane Park Carson Simpson Katie Patel Source Type: research
Systemic-Sclerosis-Related Interstitial Lung Disease: A Review of the Literature and Recommended Approach for Clinical Pharmacists
CONCLUSION: Numerous pharmacologic agents have been studied and repurposed in the treatment of SSc-ILD, with nintedanib and TCZ gaining approval to slow the rate of decline in pulmonary function in SSc-ILD. Other agents, including belimumab and pirfenidone, are on the horizon as potential treatment options; but further studies are needed to compare their efficacy and safety with the current standard of care.PMID:38095621 | DOI:10.1177/10600280231213672 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - December 14, 2023 Category: Drugs & Pharmacology Authors: Hannah Marie Ferrari Pramodini Kale-Pradhan Jewel Konja Michelle Dierker Amber Lanae Martirosov Source Type: research
Lecanemab: A Humanized Monoclonal Antibody for the Treatment of Early Alzheimer Disease
CONCLUSION: Lecanemab is a humanized monoclonal antibody that is selective for soluble amyloid-beta (Aβ) aggregates. Lecanemab has exhibited a decrease in brain Aβ plaques and moderately less decline on clinical measures of cognitive function.PMID:38095619 | DOI:10.1177/10600280231218253 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - December 14, 2023 Category: Drugs & Pharmacology Authors: Juliane Park Carson Simpson Katie Patel Source Type: research
Systemic-Sclerosis-Related Interstitial Lung Disease: A Review of the Literature and Recommended Approach for Clinical Pharmacists
CONCLUSION: Numerous pharmacologic agents have been studied and repurposed in the treatment of SSc-ILD, with nintedanib and TCZ gaining approval to slow the rate of decline in pulmonary function in SSc-ILD. Other agents, including belimumab and pirfenidone, are on the horizon as potential treatment options; but further studies are needed to compare their efficacy and safety with the current standard of care.PMID:38095621 | DOI:10.1177/10600280231213672 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - December 14, 2023 Category: Drugs & Pharmacology Authors: Hannah Marie Ferrari Pramodini Kale-Pradhan Jewel Konja Michelle Dierker Amber Lanae Martirosov Source Type: research
Lecanemab: A Humanized Monoclonal Antibody for the Treatment of Early Alzheimer Disease
CONCLUSION: Lecanemab is a humanized monoclonal antibody that is selective for soluble amyloid-beta (Aβ) aggregates. Lecanemab has exhibited a decrease in brain Aβ plaques and moderately less decline on clinical measures of cognitive function.PMID:38095619 | DOI:10.1177/10600280231218253 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - December 14, 2023 Category: Drugs & Pharmacology Authors: Juliane Park Carson Simpson Katie Patel Source Type: research
Systemic-Sclerosis-Related Interstitial Lung Disease: A Review of the Literature and Recommended Approach for Clinical Pharmacists
CONCLUSION: Numerous pharmacologic agents have been studied and repurposed in the treatment of SSc-ILD, with nintedanib and TCZ gaining approval to slow the rate of decline in pulmonary function in SSc-ILD. Other agents, including belimumab and pirfenidone, are on the horizon as potential treatment options; but further studies are needed to compare their efficacy and safety with the current standard of care.PMID:38095621 | DOI:10.1177/10600280231213672 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - December 14, 2023 Category: Drugs & Pharmacology Authors: Hannah Marie Ferrari Pramodini Kale-Pradhan Jewel Konja Michelle Dierker Amber Lanae Martirosov Source Type: research
Lecanemab: A Humanized Monoclonal Antibody for the Treatment of Early Alzheimer Disease
CONCLUSION: Lecanemab is a humanized monoclonal antibody that is selective for soluble amyloid-beta (Aβ) aggregates. Lecanemab has exhibited a decrease in brain Aβ plaques and moderately less decline on clinical measures of cognitive function.PMID:38095619 | DOI:10.1177/10600280231218253 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - December 14, 2023 Category: Drugs & Pharmacology Authors: Juliane Park Carson Simpson Katie Patel Source Type: research
Systemic-Sclerosis-Related Interstitial Lung Disease: A Review of the Literature and Recommended Approach for Clinical Pharmacists
CONCLUSION: Numerous pharmacologic agents have been studied and repurposed in the treatment of SSc-ILD, with nintedanib and TCZ gaining approval to slow the rate of decline in pulmonary function in SSc-ILD. Other agents, including belimumab and pirfenidone, are on the horizon as potential treatment options; but further studies are needed to compare their efficacy and safety with the current standard of care.PMID:38095621 | DOI:10.1177/10600280231213672 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - December 14, 2023 Category: Drugs & Pharmacology Authors: Hannah Marie Ferrari Pramodini Kale-Pradhan Jewel Konja Michelle Dierker Amber Lanae Martirosov Source Type: research
Lecanemab: A Humanized Monoclonal Antibody for the Treatment of Early Alzheimer Disease
CONCLUSION: Lecanemab is a humanized monoclonal antibody that is selective for soluble amyloid-beta (Aβ) aggregates. Lecanemab has exhibited a decrease in brain Aβ plaques and moderately less decline on clinical measures of cognitive function.PMID:38095619 | DOI:10.1177/10600280231218253 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - December 14, 2023 Category: Drugs & Pharmacology Authors: Juliane Park Carson Simpson Katie Patel Source Type: research
Systemic-Sclerosis-Related Interstitial Lung Disease: A Review of the Literature and Recommended Approach for Clinical Pharmacists
CONCLUSION: Numerous pharmacologic agents have been studied and repurposed in the treatment of SSc-ILD, with nintedanib and TCZ gaining approval to slow the rate of decline in pulmonary function in SSc-ILD. Other agents, including belimumab and pirfenidone, are on the horizon as potential treatment options; but further studies are needed to compare their efficacy and safety with the current standard of care.PMID:38095621 | DOI:10.1177/10600280231213672 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - December 14, 2023 Category: Drugs & Pharmacology Authors: Hannah Marie Ferrari Pramodini Kale-Pradhan Jewel Konja Michelle Dierker Amber Lanae Martirosov Source Type: research
Lecanemab: A Humanized Monoclonal Antibody for the Treatment of Early Alzheimer Disease
CONCLUSION: Lecanemab is a humanized monoclonal antibody that is selective for soluble amyloid-beta (Aβ) aggregates. Lecanemab has exhibited a decrease in brain Aβ plaques and moderately less decline on clinical measures of cognitive function.PMID:38095619 | DOI:10.1177/10600280231218253 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - December 14, 2023 Category: Drugs & Pharmacology Authors: Juliane Park Carson Simpson Katie Patel Source Type: research
Systemic-Sclerosis-Related Interstitial Lung Disease: A Review of the Literature and Recommended Approach for Clinical Pharmacists
CONCLUSION: Numerous pharmacologic agents have been studied and repurposed in the treatment of SSc-ILD, with nintedanib and TCZ gaining approval to slow the rate of decline in pulmonary function in SSc-ILD. Other agents, including belimumab and pirfenidone, are on the horizon as potential treatment options; but further studies are needed to compare their efficacy and safety with the current standard of care.PMID:38095621 | DOI:10.1177/10600280231213672 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - December 14, 2023 Category: Drugs & Pharmacology Authors: Hannah Marie Ferrari Pramodini Kale-Pradhan Jewel Konja Michelle Dierker Amber Lanae Martirosov Source Type: research
Safety and Effectiveness of a Standardized Intravenous Insulin Infusion Order Set for Managing Uncontrolled Hyperglycemia Outside the Intensive Care Unit
CONCLUSION AND RELEVANCE: Our findings support the safe administration of IV insulin infusions to non-ICU patients when targeting a glucose range of 140 to 180 mg/dL and limiting the infusion duration.PMID:38084454 | DOI:10.1177/10600280231178876 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - December 12, 2023 Category: Drugs & Pharmacology Authors: Francisco Ibarra Source Type: research
